MetLife Stock - Weekly review against US insurers
19.06.2026 - 21:44:23 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:41 CET. Details in the imprint.
MetLife (US59156R1086) is ending the week trading near record territory on the New York Stock Exchange. The stock continues to be assessed in the context of the broader US life insurance sector, where investors are weighing rates, credit quality and capital returns.
All news and analysis on MetLife stock
Current articles, regulatory filings and historical data provide additional context for MetLife’s valuation and its position among major US insurers.
How MetLife shares performed this week
MetLife shares recently changed hands around the mid-$80s, after closing at $85.76 on 06/18/2026, up 0.2% on the day according to MarketBeat data. Extended trading that evening indicated a price of $86.22, keeping the stock close to its 52-week high.
Quote data from another major platform shows an intraday range between roughly $82.69 and $84.26 in the latest regular session, with a 52-week band stretching from about $57.91 to $84.26. Against this backdrop, the stock’s move from the high-$50s to the mid-$80s over twelve months underlines a robust rerating.
Position in the US life insurance peer group
MetLife is widely compared with other large US and global life insurers, including Prudential Financial, Lincoln National and Aflac. The company serves around 100 million customers in more than 40 countries, which gives it a scale advantage versus some US-focused peers.
Sector investors have been reassessing life insurers as higher interest rates improve investment yields but also raise questions about credit risk. On balance, large diversified players like MetLife, with broad geographic and product exposure, are often seen as better positioned to navigate rate cycles than smaller single-market insurers.
What consensus expectations signal
Analyst consensus compiled on several financial platforms still points to MetLife as a core holding within US insurance, with a mix of Buy and Hold ratings and very few formal Sell recommendations. Target prices cluster moderately above the current market quotation, indicating limited but positive upside in many models.
Consensus earnings forecasts imply that investors expect stable to gradually rising earnings per share over the next couple of years, helped by investment income and ongoing cost discipline. Any significant revision to these forecasts around upcoming quarterly results could quickly be reflected in the shares.
How MetLife makes its money
MetLife generates most of its revenue from life insurance, annuities and employee benefits, complemented by asset management services through its institutional investment arm. The product mix spans individual life policies, retirement and income products, dental and disability coverage, as well as group benefits for corporate and public-sector clients.
Where the stock trades today
The shares of MetLife (US59156R1086) trade on the New York Stock Exchange at $87.43 as of 06/19/2026, 00:45 EDT.
MetLife at a glance
- Company: MetLife Inc.
- ISIN: US59156R1086
- WKN: 934623
- Ticker: MET
- Venue: NYSE
- Price (as of 06/19/2026, 00:45 EDT): 87.43 USD
- Market cap: 61,000,000,000 USD (as of 06/19/2026)
- Sector / Industry: Financials / Life & Health Insurance
- Index membership: S&P 500
- Next earnings date: 10/30/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
